Breakthrough solutions to enable cost effective and
scalable cell culture

CellRev work with developers of cell-based vaccines, therapies, and drugs to progress novel treatments from discovery to manufacturing. Our products and protocols address significant bottlenecks including aggregation, clumping, and process translatability.

Bioprocessing Solutions

CellRev’s continuous platform offers seamless translation from research to market with superior automation, control, and stability versus existing technologies.

Our patented biomanufacturing platform is founded on the ability to continuously grow, detach, and then collect adherent cells.

Applications include food, therapies, and biopharmaceuticals with data available on several cell lines including VERO, HACAT, and iPSCs.

We work with customers at any stage of process development to unlock bottlenecks in existing processes or commission our continuous platform. CellRev utilises a combination of their proprietary reagents and in-house process development expertise to design or improve adherent cell culture solutions for Biotech SMEs, CDMOs, and Biopharma manufacturers.

Explore

Benefits

3x increase
in bioreactor productivity 

40-60% reduction
in labour costs

 

Up to 95% reduction
on single-use waste consumables

Up to 57% reduction
in CAPEX at scale

Applications

Cultured Meat & Seafood
 
Cultivated meat & seafood producers face countless scalability challenges, particularly as they strive to achieve price-parity with conventionally grown meat products.
 
The technologies developed by CellRev will be of critical importance in establishing cultivated meat as a realistic, viable, and attractive alternative to factory farming, meeting the world’s growing demand for food.

The Technology

Cell Therapies
 
Progress continues to be made in allogeneic cell therapies, but with supply bottlenecks projected, it is still unknown how many of these life-saving solutions will make it to market in the coming years.
 
Our automated closed-loop system has the potential to provide superior cell expansion solutions in the years ahead.
 
 
Cell Therapies
 
Progress continues to be made in allogeneic cell therapies, but with supply bottlenecks projected, it is still unknown how many of these life-saving solutions will make it to market in the coming years.
 
Our automated closed-loop system has the potential to provide superior cell expansion solutions in the years ahead.
 
 

CellRev’s continuous cell processing platform is compatible with all adherent cell culture processes.

Contact us to discuss your requirements.

Our Partners

News and Insight

To stay up to date with our latest product updates and innovations, join our mailing list below.

BSF Enterprise the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues (3DBT) and corneal tissue …

CellRev launches its proprietary media additive AggreGuard™ which prevents aggregation of adherent cells and increases cell yield in existing VERO processes CellRev, …

Cell culture is at the cutting edge of biological innovation. However, the need to reach commercial scale presents many practical, scientific, regulatory, …

CellRev sign JDA with Saint-Gobain Life Sciences to develop a groundbreaking media rejuvenation process CellRev, the bioprocessing company revolutionising adherent cell cultivation, …

At CellRev, we are working towards a bright future for adherent cell culture across industries such as cultured meat and seafood, cell …

BSF Enterprise the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues (3DBT) and corneal tissue …

CellRev launches its proprietary media additive AggreGuard™ which prevents aggregation of adherent cells and increases cell yield in existing VERO processes CellRev, …

Cell culture is at the cutting edge of biological innovation. However, the need to reach commercial scale presents many practical, scientific, regulatory, …

CellRev sign JDA with Saint-Gobain Life Sciences to develop a groundbreaking media rejuvenation process CellRev, the bioprocessing company revolutionising adherent cell cultivation, …

BSF Enterprise the Main Market listed biotech company and owner of pioneering UK-based tissue engineering company 3D Bio-Tissues (3DBT) and corneal tissue …

CellRev launches its proprietary media additive AggreGuard™ which prevents aggregation of adherent cells and increases cell yield in existing VERO processes CellRev, …

Cell culture is at the cutting edge of biological innovation. However, the need to reach commercial scale presents many practical, scientific, regulatory, …